Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Jul 07, 2022 1:41pm
137 Views
Post# 34808961

RE:Volume

RE:Volume
badger13 wrote: Wow what's driving the trading volume today?


$132,000 worth of stock traded so far today on all Canadian markets. That amount of volume could be anything. We have now entered an important quarter for CZO, however, as key data from multiple programs is expected along with the approval to commence the avenanthramide clinical trial.

The next less than 90 days:

- Q2 results and potential outlook for the rest of the year. Has the momentum continued?
- A delivery technology needs delivery data to validate it. Delivery data for PGX-Alginate/CoQ10, PGX-YBG/CoQ10, and PGX-Alginate-YBG/CoQ10 is ahead. Is PGX-YBG-Alginate/CoQ10 a new masterpiece? This makes the way for a potential licensing deal.
- PBG-YBG fibrosis data with McMaster. 
- The Angiogenesis Foundation study was to last 1 year and that concludes in August.
- Avenanthramide clinical trial expected to be initiated with potential safety and hints of efficacy early. With avenanthramide already safe efficacy may be the only risk.




<< Previous
Bullboard Posts
Next >>